Latest Articles
Exploring the Power Of Progesterone: Bioidentical Hormone Replacement Therapy For Women's Health With Carol Peterson... - iVoox
Exploring the Power Of Progesterone: Bioidentical Hormone Replacement Therapy For Women's Health With Carol Peterson... iVoox
Published: Nov. 14, 2024, 7:44 p.m.
Exploring the Power Of Progesterone: Bioidentical Hormone Replacement Therapy For Women's Health With Carol Peterson... - ivoox.com
Exploring the Power Of Progesterone: Bioidentical Hormone Replacement Therapy For Women's Health With Carol Peterson... ivoox.com
Published: Nov. 14, 2024, 7:44 p.m.
Cartherics: Interview With CEO Prof. Alan Trounson About The Cell Therapy Company - Pulse 2.0
Cartherics: Interview With CEO Prof. Alan Trounson About The Cell Therapy Company Pulse 2.0
Published: Nov. 14, 2024, 1:02 p.m.
Relugolix Combination Therapy Improves Pain, Functioning, and Quality of Life in Women with... - Medical Dialogues
Relugolix Combination Therapy Improves Pain, Functioning, and Quality of Life in Women with... Medical Dialogues
Published: Nov. 11, 2024, 3:45 p.m.
Relugolix Combination Therapy Improves Pain, Functioning, and Quality of Life in Women with Endometriosis: Study - Medical Dialogues
Relugolix Combination Therapy Improves Pain, Functioning, and Quality of Life in Women with Endometriosis: Study Medical Dialogues
Published: Nov. 11, 2024, 3:45 p.m.
Female hormone therapy treating early menopause can also preserve cancer patients’ fertility - KBR
Female hormone therapy treating early menopause can also preserve cancer patients’ fertility KBR
Published: Nov. 8, 2024, 5:29 a.m.
Nouscom's Off-the-Shelf Neoantigen Immunotherapy, NOUS-209, Continues to Elicit Potent and Durable Immune Responses in Lynch Syndrome Carriers Highlighting its Potential to 'Intercept' Cancer - The Manila Times
Nouscom's Off-the-Shelf Neoantigen Immunotherapy, NOUS-209, Continues to Elicit Potent and Durable Immune Responses in Lynch Syndrome Carriers Highlighting its Potential to 'Intercept' Cancer The Manila Times
Published: Nov. 5, 2024, 2:11 p.m.
Lisata Therapeutics partners with University of Cincinnati to investigate endometriosis therapy - ICYMI - Proactive Investors USA
Lisata Therapeutics partners with University of Cincinnati to investigate endometriosis therapy - ICYMI Proactive Investors USA
Published: Nov. 2, 2024, noon
MMR Status Doesn’t Impact Outcomes of Chemo in Endometrial Cancer - Cancer Therapy Advisor
MMR Status Doesn’t Impact Outcomes of Chemo in Endometrial Cancer Cancer Therapy Advisor
Published: Oct. 29, 2024, 2:30 p.m.
Brachytherapy With Modified Rotte-y Applicator for Inoperable Endometrial Cancer: A Case Report - Cureus
Brachytherapy With Modified Rotte-y Applicator for Inoperable Endometrial Cancer: A Case Report Cureus
Published: Oct. 27, 2024, 7:49 a.m.
Link copied to clipboard!